Phase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia (Q54400913): Preview

Phase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia (Q54400913)
scientific article

Language:

Current Data About Phase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia

(P31)

(Q13442814)

(P248)
(P698)	3476204
(P813)	Tuesday, May 29, 2018
(P854)	http://europepmc.org/abstract/MED/3476204

(P50)

(Q89187648)

(P1545)	3
(P1932)	Champlin RE

(P248)
(P698)	3476204
(P813)	Tuesday, May 29, 2018
(P854)	http://europepmc.org/abstract/MED/3476204

(P304)

881-882

(P248)
(P698)	3476204
(P813)	Tuesday, May 29, 2018
(P854)	http://europepmc.org/abstract/MED/3476204

(P433)

(P248)
(P698)	3476204
(P813)	Tuesday, May 29, 2018
(P854)	http://europepmc.org/abstract/MED/3476204

(P478)

(P248)
(P698)	3476204
(P813)	Tuesday, May 29, 2018
(P854)	http://europepmc.org/abstract/MED/3476204

(P577)

Tuesday, September 1, 1987

(P248)
(P698)	3476204
(P813)	Tuesday, May 29, 2018
(P854)	http://europepmc.org/abstract/MED/3476204

(P921)

(Q180983)

(P887)

(P1433)

(Q27710285)

(P248)
(P698)	3476204
(P813)	Tuesday, May 29, 2018
(P854)	http://europepmc.org/abstract/MED/3476204

(P1476)

"Phase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia" (language: en)

(P248)
(P698)	3476204
(P813)	Tuesday, May 29, 2018
(P854)	http://europepmc.org/abstract/MED/3476204

(P2093)

Decker RW

(P1545)	1

(P248)
(P698)	3476204
(P813)	Tuesday, May 29, 2018
(P854)	http://europepmc.org/abstract/MED/3476204

Ho WG

(P1545)	2

(P248)
(P698)	3476204
(P813)	Tuesday, May 29, 2018
(P854)	http://europepmc.org/abstract/MED/3476204

other details

description	scientific article

External Links

(P698)	3476204